Document is current
Any future updates will be listed below
-
Authors
Kamenicky, Peter https://orcid.org/0000-0002-1994-4226
Briot, Karine https://orcid.org/0000-0002-6238-2601
Brandi, Maria Luisa https://orcid.org/0000-0002-8741-0592
Cohen-Solal, Martine https://orcid.org/0000-0002-8582-8258
Crowley, Rachel K https://orcid.org/0000-0003-1472-4117
Keen, Richard
Kolta, Sami
Lachmann, Robin H https://orcid.org/0000-0002-2618-2581
Lecoq, Anne-Lise
Ralston, Stuart H https://orcid.org/0000-0002-2804-7586
Walsh, Jennifer S
Rylands, Angela J
Williams, Angela
Sun, Wei
Nixon, Annabel https://orcid.org/0000-0003-3454-9491
Nixon, Mark
Javaid, Muhammad K https://orcid.org/0000-0001-7985-0048
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02526160 at ClinicalTrials.govnct03920072 at ClinicalTrials.govDocuments that mention this clinical trial
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
https://doi.org/10.1136/rmdopen-2021-001714
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
nct04308096 at ClinicalTrials.govDocuments that mention this clinical trial
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
Documents that mention this clinical trial
Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies
https://doi.org/10.1007/s12325-022-02412-x
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
https://doi.org/10.1136/rmdopen-2022-002676
-
Funding
Funding for this research was provided by:
Kyowa Kirin International plc
Ultragenyx Pharmaceutical
- License Information
